TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: New bone in contact with the implant surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Airway localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality associated with serum MBL levels
Endpoint domain: Mortality/survival
Primary endpoint: Incidence and Severity of Ocular Adverse Events in the Study Eye
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Ocular Adverse Events in the Fellow Eye
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Non-Ocular Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Serotonin release capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma and urine concentration of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response rate according to hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion requirement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Predictive value of reticulocyte increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Study related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tissue Testosterone and Dihydrotestosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Official School Absences
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Official Arrest Records
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: General Well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Health Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of HIV diagnostic test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in High Sensitivity-C Reactive Protein (Serum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Development of symptomatic illness confirmed as influenza A
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate ratio for malignancies of hematologic system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sense of security of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of high order aberrations after refractive surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall disease activity score using ACRODAT®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygenated hemoglobin ratio of total hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Child Involvement Ratings Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Adherence Checklist-Revised
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SARS-CoV 2 infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Lateral hip movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-traumatic stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-traumatic growth levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean absolute change in visceral adipose tissue mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of serious cardiac adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Potentially Clinically Significant Laboratory Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LDL-c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fistula Suitability for Dialysis at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lymph Nodes number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clavien Dindo score (post-operative complications)
Endpoint domain: Adverse events/effects
Primary endpoint: MACE (Major Adverse Cardiovascular Events)-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Ophthalmic artery blood flow rate changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in upper extremity problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in upper extremity functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: AUClast of amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of valsartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Referred
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median 2 year survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of days absent from daycare due to infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Efficacy of AUY922 in combination with trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of adverse events defined as dose-limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: opioids consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Narcotic Consumption in Morphine Equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in chest wall V30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation outcomes
Primary endpoint: Change in Combined Circumference Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in percent time spent sedentary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to needed tests and treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: clinical benefit rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactical Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Implant Passing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vaginal Cuff Dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Patient behavioral intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage Change From Baseline in Peripheral Blood Immune Cell (PBIC) Subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage Change From Baseline in Serum Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24 hour breast milk volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of AV-Block > I°
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Whose Tumor Position is Visible Within ~2mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Fimasartan and Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUCt) of Fimasartan and Atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day pint prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in MADRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum progesterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CRE Decolonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Sost Values for 6th Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dkk-1 Values for 6th Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Serotypes of Streptococcus Pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean time to 90% TOF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants presenting a temperature rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antibody titers to influenza strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Waist circumference cut off levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vital Signs Abnormalities of Potential Clinical Concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Abnormalities of Potential Clinical Concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen saturation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse rate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tattoo Clearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quiet standing balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed-up and Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of elastography features of transplanted kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Qualitative measure of Deaf participants' views
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of immunocryosurgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: maximum change from baseline in HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-tumour efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Qualitative assessment vector velocity fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast-to-background ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vector correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Function Analysis (closing time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Aggreguide aggregometry (clotting analyses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentration measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complications associated with anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Social Responsiveness Scale (SRS) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: serum chloride difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endothelial progenitor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diffusion kinetics of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pseudoexfoliation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Sleep Duration
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Weight gain in pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of participants with harms associated with the index procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of surgical, minimally invasive intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Anti-Erythropoietin Antibodies (ADA) formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Device- and Procedure-related Adverse Events at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to Understand Speech in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of cough, wheeze and shortness of breath
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Optical Coherence Tomography (OCT) Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drain fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of estimated glomerular filtration rate by 50 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SLE Response Index (SRI) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment of positive, negative, and cognitive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety assessed with UKU scale
Endpoint domain: Adverse events/effects
Primary endpoint: Neurocognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of Carbon Monoxide (CO) Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC and raltegravir trough concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes of the Eating Assessment Tool-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of the Functional Oral Intake Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of the Mini Nutritional Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of the Council on Nutrition Appetite Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of the Dietary Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes of the Swallowing Quality of Life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global bipolar and unipolar signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local bipolar and unipolar signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse patient outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin barrier dysfunction via skin tape stripping (STS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin barrier dysfunction via transepidermal water loss (TEWL) measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of subjects diagnosed with small bowel Crohn's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maintenance of erection in men with ED
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of their female partners sexual quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electronic Instrumental activities of daily living Satisfaction Assessment (EISA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in ICD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 1-hour Pad Weight Test From Baseline to 24 Month Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Pad Weight Test From Baseline to 24 Month Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects in Each Range of Pads Per Day Use
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Coronary artery cannulation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Thermal energy at hot tap of bath
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of initiation of positive pressure ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: absolute change in the average weekly PSS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HSIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Each of the Methods of APTIMA Assay at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of HSIL Among Women Who Were HRA Negative for HSIL at Study Entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Twelve-month Progression-free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Presence of a Grade A Posterior Vitreous Detachment (PVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum-tolerated Dose (MTD) of Inotuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air exchange
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to successful cannulation of the femoral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PELD Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anthropometric Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resection rate of colorectal polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of women with histological diagnosis of CIN2+ in colposcopy-directed biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of women with histological diagnosis of CIN2 or worse in DSI-directed biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of women with histological diagnosis of CIN2 or worse in additional random biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the Short Warwick-Edinburgh Mental Well-being Scale (SWEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Freedom of PSA progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevention of chemotherapy induced nausea and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Who Had One or More Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects